From January 1, 2024 to March 31, 2024, the company has repurchased 239,555 shares, representing 0.003912% for CNY 10 million. With this, the company has completed the repurchase of 14,351,878 shares, representing 0.23% for CNY 634.67 million under the buyback announced on May 15, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
46.16 CNY | -0.04% | +10.27% | +2.06% |
Apr. 26 | Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3% | MT |
Apr. 17 | Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.06% | 40.56B | |
+34.00% | 664B | |
+29.29% | 567B | |
-7.75% | 354B | |
+18.53% | 330B | |
+4.95% | 286B | |
+13.79% | 234B | |
+4.93% | 199B | |
-9.78% | 196B | |
-4.89% | 148B |
- Stock Market
- Equities
- 600276 Stock
- News Jiangsu Hengrui Medicine Co., Ltd.
- Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.